The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 11, 2020
Filed:
May. 26, 2016
Applicant:
Amphivena Therapeutics, Inc., South San Francisco, CA (US);
Inventors:
Luke Evnin, San Francisco, CA (US);
Jeanmarie Guenot, San Francisco, CA (US);
Lori Kunkel, San Francisco, CA (US);
Assignee:
Amphivena Therapeutics, Inc., South San Francisco, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61P 35/02 (2006.01); A61K 51/10 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2809 (2013.01); A61K 51/10 (2013.01); A61P 35/02 (2018.01); C07K 16/2803 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01);
Abstract
Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).